Literature DB >> 30287978

Neonatal Micro-RNA Profile Determines Endothelial Function in Offspring of Hypertensive Pregnancies.

Grace Z Yu1,2, Svetlana Reilly1, Adam J Lewandowski1, Christina Y L Aye1,3, Lisa J Simpson1,2, Laura Newton1, Esther F Davis1, Sha J Zhu4, Willow R Fox1, Anuj Goel1,4, Hugh Watkins1, Keith M Channon1, Suzanne M Watt2, Theodosios Kyriakou1,4, Paul Leeson1.   

Abstract

Offspring of hypertensive pregnancies are at increased risk of developing hypertension in adulthood. In the neonatal period they display endothelial cell dysfunction and altered microvascular development. MicroRNAs, as important endothelial cellular regulators, may play a role in this early endothelial dysfunction. Therefore we identified differential microRNA patterns in endothelial cells from offspring of hypertensive pregnancies and determined their role in postnatal vascular cell function. Studies were performed on human umbilical vein endothelial cell (HUVECs) samples from 57 pregnancies. Unbiased RNA-sequencing identified 30 endothelial-related microRNAs differentially expressed in HUVECs from hypertensive compared to normotensive pregnancies. Quantitative reverse transcription PCR (RT-qPCR) confirmed a significant higher expression level of the top candidate, miR-146a. Combined miR-146a targeted gene expression and pathway analysis revealed significant alterations in genes involved in inflammation, angiogenesis and immune response in the same HUVECs. Elevated miR-146a expression level at birth identified cells with reduced ability for in vitro vascular tube formation, which was rescued by miR-146a inhibition. In contrast, miR-146a overexpression significantly reduced vascular tube formation in HUVECs from normotensive pregnancies. Finally, we confirmed that mir146a levels at birth predicted in vivo microvascular development during the first three postnatal months. Offspring of hypertensive pregnancy have a distinct endothelial regulatory microRNA profile at birth, which is related to altered endothelial cell behaviour, and predicts patterns of microvascular development during the first three months of life. Modification of this microRNA profile in vitro can restore impaired vascular cell function.

Entities:  

Keywords:  Hypertensive pregnancy; microRNAs; postnatal vasculogenesis

Mesh:

Substances:

Year:  2018        PMID: 30287978      PMCID: PMC6166786          DOI: 10.1161/HYPERTENSIONAHA.118.11343

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Maternal cigarette smoking during pregnancy is associated with downregulation of miR-16, miR-21, and miR-146a in the placenta.

Authors:  Matthew A Maccani; Michele Avissar-Whiting; Carolyn E Banister; Bethany McGonnigal; James F Padbury; Carmen J Marsit
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

3.  MicroRNAs modulate the angiogenic properties of HUVECs.

Authors:  Laura Poliseno; Andrea Tuccoli; Laura Mariani; Monica Evangelista; Lorenzo Citti; Keith Woods; Alberto Mercatanti; Scott Hammond; Giuseppe Rainaldi
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

4.  Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism?

Authors:  Merzaka Lazdam; Arancha de la Horra; Alex Pitcher; Zola Mannie; Jonathan Diesch; Corinne Trevitt; Ilias Kylintireas; Hussain Contractor; Atul Singhal; Alan Lucas; Stefan Neubauer; Rajesh Kharbanda; Nicholas Alp; Brenda Kelly; Paul Leeson
Journal:  Hypertension       Date:  2010-05-17       Impact factor: 10.190

Review 5.  MicroRNAs in pregnancy.

Authors:  Diana M Morales Prieto; Udo R Markert
Journal:  J Reprod Immunol       Date:  2011-02-25       Impact factor: 4.054

6.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

7.  MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4.

Authors:  Ke Yang; Yu Song He; Xiao Qun Wang; Lin Lu; Qiu Jing Chen; Jing Liu; Zhen Sun; Wei Feng Shen
Journal:  FEBS Lett       Date:  2011-02-15       Impact factor: 4.124

8.  MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.

Authors:  Angelika Bonauer; Guillaume Carmona; Masayoshi Iwasaki; Marina Mione; Masamichi Koyanagi; Ariane Fischer; Jana Burchfield; Henrik Fox; Carmen Doebele; Kisho Ohtani; Emmanouil Chavakis; Michael Potente; Marc Tjwa; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

9.  Hypertension: Hypertension in pregnancy: a risk factor for the whole family?

Authors:  Grace Z Yu; Paul Leeson
Journal:  Nat Rev Nephrol       Date:  2017-04-19       Impact factor: 28.314

Review 10.  Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies.

Authors:  Esther F Davis; Laura Newton; Adam J Lewandowski; Merzaka Lazdam; Brenda A Kelly; Theodosios Kyriakou; Paul Leeson
Journal:  Clin Sci (Lond)       Date:  2012-07       Impact factor: 6.124

View more
  9 in total

Review 1.  Preterm Birth Is a Novel, Independent Risk Factor for Altered Cardiac Remodeling and Early Heart Failure: Is it Time for a New Cardiomyopathy?

Authors:  Holger Burchert; Adam J Lewandowski
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-14

Review 2.  The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life.

Authors:  Cheryl Mei Jun Tan; Adam James Lewandowski
Journal:  Fetal Diagn Ther       Date:  2019-09-18       Impact factor: 2.587

Review 3.  Current Updates on Pre-eclampsia: Maternal and Foetal Cardiovascular Diseases Predilection, Science or Myth? : Future cardiovascular disease risks in mother and child following pre-eclampsia.

Authors:  Samson A Odukoya; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2021-03-10       Impact factor: 5.369

Review 4.  Epigenetic regulation of pediatric and neonatal immune responses.

Authors:  Jennifer Bermick; Matthew Schaller
Journal:  Pediatr Res       Date:  2021-07-08       Impact factor: 3.756

5.  Does osteogenic potential of clonal human bone marrow mesenchymal stem/stromal cells correlate with their vascular supportive ability?

Authors:  Alison T Merryweather-Clarke; David Cook; Barbara Joo Lara; Peng Hua; Emmanouela Repapi; Neil Ashley; Shiang Y Lim; Suzanne M Watt
Journal:  Stem Cell Res Ther       Date:  2018-12-19       Impact factor: 6.832

Review 6.  Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring.

Authors:  Rachael Fox; Jamie Kitt; Paul Leeson; Christina Y L Aye; Adam J Lewandowski
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

7.  Prenatal and Postnatal Cardiac Development in Offspring of Hypertensive Pregnancies.

Authors:  Christina Y L Aye; Adam J Lewandowski; Pablo Lamata; Ross Upton; Esther Davis; Eric O Ohuma; Yvonne Kenworthy; Henry Boardman; Annabelle L Frost; Satish Adwani; Kenny McCormick; Paul Leeson
Journal:  J Am Heart Assoc       Date:  2020-04-30       Impact factor: 5.501

Review 8.  An Overview of Vascular Dysfunction and Determinants: The Case of Children of African Ancestry.

Authors:  Edna N Matjuda; Godwill Azeh Engwa; Constance R Sewani-Rusike; Benedicta N Nkeh-Chungag
Journal:  Front Pediatr       Date:  2021-12-10       Impact factor: 3.418

Review 9.  The Immediate and Long-Term Impact of Preeclampsia on Offspring Vascular and Cardiac Physiology in the Preterm Infant.

Authors:  Annabelle L Frost; Katie Suriano; Christina Y L Aye; Paul Leeson; Adam J Lewandowski
Journal:  Front Pediatr       Date:  2021-05-31       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.